- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about NVS
Recent news which mentions NVS
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
April 16, 2024
From Benzinga
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.
April 14, 2024
From Motley Fool
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
April 11, 2024
From Benzinga
Why Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday?
April 10, 2024
From Benzinga
From InvestorPlace
Jack Ma Is Giving Alibaba (BABA) Stock a Big Boost
April 10, 2024
From InvestorPlace
From InvestorPlace
From Benzinga
From Benzinga
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population
April 08, 2024
From Benzinga
Why Is Novartis Stock Trading Higher On Thursday?
April 04, 2024
From Benzinga
Harnessing AI for Drug Discovery: Top 3 Stocks to Watch
March 26, 2024
From InvestorPlace
From Benzinga
Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge
March 22, 2024
From Benzinga
From Benzinga
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
March 19, 2024
From Benzinga
FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer
March 15, 2024
From Benzinga
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach'
March 11, 2024
From Benzinga
3 Dividend Stocks to Buy Hand Over Fist in March
March 10, 2024
From Motley Fool
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
March 08, 2024
From Benzinga
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
March 07, 2024
From Benzinga
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers
March 06, 2024
From Benzinga
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic
March 05, 2024
From Benzinga
Novartis Reveals Promising Gene Therapy Data for Treating Spinal Muscular Atrophy in Older Children
March 04, 2024
From Benzinga
3 Stocks Primed for Exponential Returns by 2034
March 01, 2024
From InvestorPlace
2 Dividend Stocks to Buy and Hold Forever
February 29, 2024
From Motley Fool
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
February 28, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.